Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women

被引：20

作者：

Alacacioglu, I ^{[1
]}

Özcan, MA ^{[1
]}

Alacacioglu, A ^{[1
]}

Polat, M ^{[1
]}

Yüksel, F ^{[1
]}

Demirkan, F ^{[1
]}

Piskin, Ö ^{[1
]}

Özgenç, Y ^{[1
]}

Özsan, HG ^{[1
]}

Undar, B ^{[1
]}

机构：

[1] Dokuz Eylul Univ, Inst Oncol, Div Hematol, TR-35340 Izmir, Turkey

来源：

THROMBOSIS RESEARCH | 2004年 / 114卷 / 03期

关键词：

preeclampsia; coagulation; fibrinolysis; thrombin activable fibrinolysis inhibitor;

D O I：

10.1016/j.thromres.2004.05.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To explain the pathogenesis of preeclampsia with coagulation induction or a defective fibrinolysis, various hemostatic parameters were studied and different treatment modalities targeting these parameters were evaluated. Considering the role of TAFI in down-regulation of fibrinolysis, in our study we have investigated whether TAFI contributes to impaired fibrinolysis in patient with preeclampsia. Thirty patients with preeclampsia (mean age +/- SD 25.7 +/- 4.53; range 17-36) and 30 normal pregnant women as control group (mean age +/- SD 28 +/- 5.26; range 21-38) were included in our study. TAFI antigen was determined using an ELISA kit for quantitative measurement. The mean TAFI antigen levels were 12.55 +/- 1.88 mug/ml in patients with preeclampsia and 12.29 +/- 3.0 mug/ml in normal pregnant women. A statistically significant difference was not found between TAFI antigen levels of two groups (p>0.05). In order to clarify the role of TAFI in the pathogenesis of preeclampsia, in addition to plasma TAFI levels, its synthesis, activation and metabolism should also be evaluated. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：155 / 159

页数：5

共 21 条

[1] How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review [J].

Alfirevic, Z ;

Roberts, D ;

Martlew, V .

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2002, 101 (01) :6-14

[2]

Antovic JP, 2002, THROMB HAEMOSTASIS, V88, P644

[3] TAFI antigen and D-dimer levels during normal pregnancy and at delivery [J].

Chabloz, P ;

Reber, G ;

Boehlen, F ;

Hohlfeld, P ;

de Moerloose, P .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :150-152

[4] Plasma TAFI antigen variations in healthy subjects [J].

Chetaille, P ;

Alessi, MC ;

Kouassi, D ;

Morange, PE ;

Juhan-Vague, I .

THROMBOSIS AND HAEMOSTASIS, 2000, 83 (06) :902-905

[5] THE CLASSIFICATION AND DEFINITION OF THE HYPERTENSIVE DISORDERS OF PREGNANCY [J].

DAVEY, DA ;

MACGILLIVRAY, I .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 158 (04) :892-898

[6]

Dizon-Townson D, 1998, SEMIN THROMB HEMOST, V24, P55

[7]

Gammaro L, 2001, J NEPHROL, V14, P312

[8] The influence of thrombophilic factors on the incidence of deep vein thrombosis and pregnancy complications [J].

Heilmann, L ;

von Tempelhoff, FG ;

Gerhold, S ;

Rath, W .

ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 2001, 205 (04) :128-136

[9]

HORI Y, J CLIN ENDOCRINOL ME

[10] Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of thrombin-activatable fibrinolysis inhibitor [J].

Hryszko, T ;

Malyszko, J ;

Malyszko, JS ;

Brzósko, S ;

Mysliwiec, M .

THROMBOSIS RESEARCH, 2001, 104 (04) :233-238

← 1 2 3 →